Sunday, May 3rd14.6°C
24963
25998

Merck second-quarter profit more than doubles, tops forecast

A big one-time gain and a tax benefit helped drugmaker Merck & Co. more than double second-quarter profit, improve its profit forecast and top analysts' expectations.

The maker of popular Type 2 diabetes pill Januvia said Tuesday that net income increased to $2 billion, or 68 cents per share, from $906 million, or 30 cents per share, in the same quarter a year earlier.

Merck, based in Whitehouse Station, New Jersey, said its earnings, adjusted for one-time gains and costs, were 85 cents per share. Analysts surveyed by Zacks Investment Research expected 81 cents.

Merck recorded a $741 million gain from AstraZeneca PLC, which exercised its option to buy out Merck's interest in the British drugmaker's heartburn drugs Nexium and Prilosec.

The world's fourth-biggest drugmaker's revenue fell 1 per cent to $10.93 billion, still $220 million above Wall Street expectations.

CEO Kenneth Frazier said on a conference call that Merck favours smaller acquisitions — like its $3.85 billion purchase of hepatitis C treatment developer Idenix Pharmaceuticals Inc., expected to close this quarter — and is not looking for a deal enabling it to move its legal headquarters to a country with a lower tax rate.

That strategy, called inversion, is suddenly hot in corporate America. The U.S. has the world's highest corporate tax rate, 35 per cent, but pharmaceutical companies here generally pay well under 30 per cent.

Chicago-based drugmaker AbbVie Inc. just reached a $55 billion deal to combine with British counterpart Shire PLC and incorporate in Britain.

BernsteinResearch analyst Dr. Timothy Anderson wrote to investors that Merck "will likely have another flattish year in 2014 in terms of financial performance but then growth should return more consistently."

Merck noted it expects by early next year to launch two new drugs awaiting approval: long-delayed suvorexant for insomnia and pembrolizumab for advanced melanoma. The latter is part of the promising new class of drugs that stimulate the immune system to identify and attack cancer cells.

Meanwhile, Merck got U.S. approval in April for two tablets to gradually reduce grass and ragweed allergies, and in May for anticlotting drug Zontivity.

Sales of Merck's prescription drugs fell 2 per cent to $9.09 billion. Top sellers were Type 2 diabetes pills Januvia and Janumet, up 2 per cent at $1.58 billion, and cholesterol medicines Zetia and Vytorin, up 6 per cent to a combined $1.13 billion.

Merck's consumer health segment had the biggest sales increase, up 19 per cent to $583 million. In May, Merck agreed to sell that to Germany's Bayer for $14.2 billion. It includes Claritin and the Coppertone sun-care line.

Merck said it expects full-year sales of $42.4 billion to $43.2 billion and profit of $3.43 to $3.53 per share, excluding one-time items. In January, it forecast $3.35 to $3.53.

In morning trading, Merck shares were up 72 cents at $58.69. They have increased 20 per cent in the last 12 months.

___

Follow Linda A. Johnson at www.twitter.com/LindaJ_onPharma.

The Canadian Press


Read more Business News

25990


Recent Trending




Today's Market
S&P TSX15339.77+115.25
S&P CDNX699.43+3.46
DJIA18024.06+183.54
Nasdaq5005.39+63.97
S&P 5002108.29+22.78
CDN Dollar0.8215-0.0008
Gold1174.50-4.90
Oil59.15-0.58
Lumber256.30-1.90
Natural Gas2.776+0.018

 
Okanagan Companies
Pacific Safety0.125+0.010
Knighthawk0.010.00
QHR Technologies Inc1.46-0.03
Cantex0.04+0.00
Anavex Life Sciences0.33+0.04
Metalex Ventures0.09+0.00
Russel Metals27.29-0.31
Copper Mountain Mining1.52+0.07
Colorado Resources0.10-0.00
ReliaBrand Inc0.004-0.001
Sunrise Resources Ltd0.04+0.00
Mission Ready Services0.215-0.005
Decisive Dividend Corporation1.85-0.15

 





FEATURED Property
22664141702 Lynrick Road
10093931 bedrooms
$1,200,000
more details
image2
Click here to feature your property
Please wait... loading


Not the lawsuit type

If I asked you whether you were the lawsuit type, chances are that your answer would be a resounding “NO”. Most people cringe at the thought of being involved in a lawsuit and if you don&r...


The rules are changing

In recent years, a number of countries, including England, Australia and the United States, have changed the regulatory framework that governs their financial institutions. Included have been changes ...


Buy versus rent

Consider the top five reasons to buy versus rent: #5 Experience Freedom: Home ownership will free you from the ties that bind you to a landlord...no longer will you be dependent on someone else&rsq...

_



25522




Member of BC Press Council


25143